Literature DB >> 16235320

Chinese herbal medicine for schizophrenia.

J Rathbone, L Zhang, M Zhang, J Xia, Xiehe Liu, Yanchun Yang.   

Abstract

BACKGROUND: Traditional Chinese medicine (TCM) was the main form of treatment in China for psychiatric illnesses until the development of antipsychotic drugs in the 1950's. Antipsychotic drugs have become the primary intervention for schizophrenia, although herbal medicines can still form part of the treatment.
OBJECTIVES: To review Chinese herbal medicine, used alone or as part of a TCM approach, for people with schizophrenia and related psychoses. SEARCH STRATEGY: We undertook electronic searches of the Cochrane Schizophrenia Group's register (December 2003), the Traditional Chinese Medical Literature Analysis and Retrieval Database (TCMLARS) (October 2003), Chinese Biomedical Database (CBM) (December 2003), China National Knowledge Infrastructure Database (May 2004), Complementary Medicine Database (AMED) (December 2003). We contacted the Chinese Cochrane Centre, the Cochrane Complementary Medicine Field and first authors of included studies and inspected reference lists for additional studies. SELECTION CRITERIA: We included all relevant randomised controlled trials involving people with schizophrenia-like illnesses, allocated to Chinese herbal medicine, including any Chinese herbs (single or mixture), compared with placebo/no treatment or antipsychotic drugs. DATA COLLECTION AND ANALYSIS: We independently extracted data and calculated fixed effects relative risk (RR), the 95% confidence intervals (CI) for homogeneous dichotomous data, and, where appropriate, the number needed to treat (NNT) on an intention-to-treat basis. For continuous data, we calculated weighted mean differences (WMD). MAIN
RESULTS: Only one small trial of the seven included studies truly evaluated TCM for schizophrenia. The other trials evaluated Chinese herbs for schizophrenia. We found one study comparing Chinese herbal medicine with antipsychotic drugs. Data for the global state outcome 'no change/worse' favoured people allocated to antipsychotic medication (n=90, RR 1.88 CI 1.2 to 2.9, NNH 4 CI 2 to 12). Six trials compared Chinese herbal medicine in combination with antipsychotic with antipsychotic drugs alone. One trial found global state 'not improved/worse' favoured the herbal medicine/antipsychotic combination (n=123, RR 0.19 CI 0.1 to 0.6, NNT 6 CI 5 to 11). Two studies (n=103) also found short-term data from the Clinical Global Impression scale favoured the herbal medicine plus antipsychotic group (WMD -0.46 CI -0.9 to -0.1) compared with those given only antipsychotics. Significantly fewer people in the experimental group left the study early compared with those given antipsychotics alone (n=1004, 6 RCTs, RR 0.30 CI 0.16 to 0.58, NNT 21 CI 18 to 35). Reports of constipation were significantly lower in the treatment group compared to those receiving antipsychotics (n=67, 1 RCT, RR 0.03 CI 0.0 to 0.5, NNH 2 CI 2 to 4). AUTHORS'
CONCLUSIONS: Chinese herbal medicines, given in a Western biomedical context, may be beneficial for people with schizophrenia when combined with antipsychotics. Traditional Chinese medicine is also under-evaluated, but results from one pioneering study that attempted to evaluate TCM should encourage further trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16235320      PMCID: PMC7017283          DOI: 10.1002/14651858.CD003444.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  28 in total

1.  Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

Authors:  M C Gulliford; O C Ukoumunne; S Chinn
Journal:  Am J Epidemiol       Date:  1999-05-01       Impact factor: 4.897

2.  [Comparison between therapeutic effect of Risperidone in treating different traditional Chinese medicine syndrome types of first-episode schizophrenia].

Authors:  X Cao; W Wang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2000-06

3.  Extract of Ginkgo biloba added to haloperidol was effective for positive symptoms in refractory schizophrenia.

Authors:  Michael B Knable
Journal:  Evid Based Ment Health       Date:  2002-08

4.  Issues in the meta-analysis of cluster randomized trials.

Authors:  Allan Donner; Neil Klar
Journal:  Stat Med       Date:  2002-10-15       Impact factor: 2.373

5.  [Clinical study of shuizhi-dahuang mixture in treating schizophrenics with blood stasis syndrome].

Authors:  Y Z Zhu; B Kang; Q Q Zhu
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  1996-11

6.  Negative symptoms in schizophrenia. Definition and reliability.

Authors:  N C Andreasen
Journal:  Arch Gen Psychiatry       Date:  1982-07

7.  The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia.

Authors:  X Y Zhang; D F Zhou; J M Su; P Y Zhang
Journal:  J Clin Psychopharmacol       Date:  2001-02       Impact factor: 3.153

8.  Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia.

Authors:  M Marshall; A Lockwood; C Bradley; C Adams; C Joy; M Fenton
Journal:  Br J Psychiatry       Date:  2000-03       Impact factor: 9.319

9.  A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia.

Authors:  Shi-Fu Xiao; Hai-Bo Xue; Xia Li; Chao Chen; Guan-Jun Li; Cheng-Mei Yuan; Ming-Yuan Zhang
Journal:  Neurosci Bull       Date:  2011-08       Impact factor: 5.203

10.  A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.

Authors:  X Y Zhang; D F Zhou; P Y Zhang; G Y Wu; J M Su; L Y Cao
Journal:  J Clin Psychiatry       Date:  2001-11       Impact factor: 4.384

View more
  11 in total

Review 1.  Evidence from the Cochrane Collaboration for Traditional Chinese Medicine therapies.

Authors:  Eric Manheimer; Susan Wieland; Elizabeth Kimbrough; Ker Cheng; Brian M Berman
Journal:  J Altern Complement Med       Date:  2009-09       Impact factor: 2.579

2.  Emotionless holism: factor and Rasch analysis of the Chinese Integrative Medicine Attitude Questionnaire.

Authors:  Vincent Chung; Marc Chong; Lau Chun Hong; Polly H X Ma; Samuel Y S Wong; Sian M Griffiths
Journal:  Chin J Integr Med       Date:  2012-07-22       Impact factor: 1.978

Review 3.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

4.  Oxidative stress in schizophrenia.

Authors:  Marija Bošković; Tomaž Vovk; Blanka Kores Plesničar; Iztok Grabnar
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

Review 5.  Cochrane systematic reviews of Chinese herbal medicines: an overview.

Authors:  Jing Hu; Junhua Zhang; Wei Zhao; Yongling Zhang; Li Zhang; Hongcai Shang
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

Review 6.  Chinese herbal medicine for resistant hypertension: a systematic review.

Authors:  Xingjiang Xiong; Xiaoke Li; Yuqing Zhang; Jie Wang
Journal:  BMJ Open       Date:  2015-01-30       Impact factor: 2.692

7.  Opportunities in Novel Psychotropic Drug Design from Natural Compounds.

Authors:  Siu Wa Tang; Wayne H Tang
Journal:  Int J Neuropsychopharmacol       Date:  2019-09-01       Impact factor: 5.176

Review 8.  Efficacy and safety of Suanzaoren decoction for primary insomnia: a systematic review of randomized controlled trials.

Authors:  Cheng-long Xie; Yong Gu; Wen-Wen Wang; Lin Lu; Deng-lei Fu; Ai-ju Liu; Hui-qin Li; Ji-huang Li; Yan Lin; Wen-jie Tang; Guo-qing Zheng
Journal:  BMC Complement Altern Med       Date:  2013-01-22       Impact factor: 3.659

9.  Best available evidence in cochrane reviews on herbal medicine?

Authors:  Elyad Davidson; Julia Vlachojannis; Melainie Cameron; Sigrun Chrubasik
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-12       Impact factor: 2.629

Review 10.  Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments.

Authors:  Wai Tong Chien; Annie Lk Yip
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-11       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.